Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.77 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112177 | 0.92 | TLR8 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL5113123 | 0.90 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL1895870 | 0.89 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL5109100 | 0.88 | TLR7 (0.60) | TLR7TLR8NUDT1 | |
| SCHEMBL29182347 | 0.88 | TLR7 (0.94) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL483385 | 0.87 | TLR7 (1.00) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL29371102 | 0.87 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL13999936 | 0.85 | TLR8 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL13999853 | 0.84 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL5113045 | 0.84 | TLR8 (0.82) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-07 | — | — | US | claimed |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | claimed |
| US-6677347-B2 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; VIRICIDED, IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | claimed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | claimed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-07 | — | — | US | disclosed |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-6677347-B2 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; VIRICIDED, IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885NUDT1 1582/4885 |
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885NUDT1 1582/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885NUDT1 1582/4885 |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885NUDT1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.